Kornimate/medical-research-clean huggingface dataset:
access to eyeglasses for school-aged children

Conditions: Myopia; Amblyopia; Hyperopia; Refractive Errors

Summary: uncorrected refractive error is a leading cause of visual impairment in children and can impact vision, quality of life, and academic performance. despite boston children's hospital serving patients from a wide range of socioeconomic backgrounds, there are health disparities in access to eyeglasses as a consequence of patients' health insurance. the investigators will examine whether the use of an in-clinic app for 3-d printed glasses reduces disparities in access to eyeglasses for our patients on medicaid. the intervention will address social determinants of health and improve pediatric health outcomes namely, how and when children having publicly funded health insurance receive eyeglasses. the short-term objectives are (1) to compare the time to receive glasses between publicly funded masshealth eyeglasses and an in-clinic order of 3d printed glasses (2) to evaluate compliance with glasses wear in these two groups, and (3) to evaluate visual function and quality-of-life outcomes in these two groups. this prospective randomized control study will evaluate barriers to accessing eyeglasses in school-aged children. the investigators will recruit children enrolled in masshealth and randomize them into two cohorts: (1) the control group will receive masshealth glasses as per standard of care, through an optical shop of their choosing, or (2) the intervention group will use an app for immediately ordering glasses (paid for by the study) in clinic following their appointment. the investigators will evaluate the time needed to receive eyeglasses, compliance with glasses wear, quality of life, and visual outcomes between the cohorts at one-, three-, and six-month intervals. through this project, the investigators will not only evaluate, quantify, and bring awareness to disparities in our patient population, but will also look toward finding a solution through the use of a novel application that addresses many of the barriers faced by patients insured through medicaid.


Eligibility criteria:
inclusion criteria: * masshealth insurance * first-time glasses wearers * receive a diagnosis of refractive amblyopia, myopia, hyperopia and/or astigmatism requiring spectacle correction for optimal vision at distance and near. * glasses must be recommended for full time wear by the attending optometrist or ophthalmologist exclusion criteria: * strabismus * developmental or learning delay * other ocular pathology
a research study to test the effectiveness of mk0217 in patients with paget's bone disease (0217-206)(completed)

Conditions: Paget's Disease of Bone

Summary: to test the safety, effectiveness of mk0217 when taken once a week for six months in treating patients with paget's bone disease.


Eligibility criteria:
inclusion criteria: * male or female, ages 18 to 90 years with a diagnosis of paget's bone disease exclusion criteria: * patient cannot stand or sit upright for at least 30 minutes * patient has difficulty swallowing or problems with digestive system

Keywords: paget's bone disease
level of deprivation assessment in a population of short-bowel syndrome patients with intestinal failure

Conditions: Short Bowel Syndrome; Intestinal Failure; Deprivation, Psychosocial

Summary: the association between social deprivation and chronic disease is regularly examined but there are no data available on patients with intestinal failure due to short bowel syndrome (sbs-if). first, the investigators aim to characterize this population and then to assess if insecurity is associated with some disease criteria.

this exploratory cross-sectional study was conducted on patients affected by intestinal failure in short bowel syndrome and monitored by the certified home parenteral nutrition (hpn) center of nancy university hospital. the investigators included all patients over 18 years old suffering from sbs-if followed-up by the certified hpn center of nancy university hospital between march 1st, 2020, and november 30th, 2023. the f-edi (a european ecological index adapted to france) was determined for each participant. the investigators set the initial date at 2020, as this corresponds to the start of the use of patient-specific formulas in the center. exclusion criteria were: not living in france, because it's required to use french-edi and patients under 18 years old because they are monitored by the children's hospital. investigators also excluded patients with transitory type 1 sbs who would have a bowel length over 2 meters after re-establishment of digestive continuity.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * suffering from short-bowel syndrome with intestinal failure * monitored by the certified home parenteral nutrition center of the nancy university hospital * between march 1st 2020 and november 30th 2023 exclusion criteria: * patients not living in france * transitory short-bowel syndrome with a predicted bowel length \> 200cm after digestive continuity
phase 2a study of vx-147 in adults with apol1-mediated focal segmental glomerulosclerosis

Conditions: Glomerulosclerosis, Focal Segmental

Summary: this study will evaluate the efficacy, safety and pharmacokinetics (pk) of vx-147 in participants with apolipoprotein l1 (apol1)-mediated focal segmental glomerulosclerosis (fsgs).


Eligibility criteria:
key inclusion criteria: * apol1 genotype of g1/g1, g2/g2, or g1/g2 * fsgs diagnosed by kidney biopsy key exclusion criteria: * evidence of non-apol1-mediated fsgs * participants with known sickle cell disease * solid organ or bone marrow transplant other protocol defined inclusion/exclusion criteria may apply.
endobronchial ultrasound guided transbronchial needle aspiration performed under general anesthesia versus moderate sedation

Conditions: Mediastinal Lymphadenopathies; Mediastinal Masses; Hilar Lymphadenopathies

Summary: the purpose of the study is to determine if there are any differences in yield or safety of endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) (a type of bronchoscopy with biopsy) performed under general anesthesia versus moderate sedation.


Eligibility criteria:
inclusion criteria: * all patients over the age of 18, evaluated by pulmonary physician that require ebus tbna for sampling of hilar and/or mediastinal lymphadenopathies or masses * patients should be considered eligible to undergo either cs or ga, without contraindications for either one of them, based on the assessment by the pulmonologist who will perform ebus-tbna exclusion criteria: * pregnancy or breastfeeding women * patients deemed poor candidates for general anesthesia by the evaluating physician (e.g., severe coronary artery disease, copd with fev1 \< 1 liter, uncontrolled hypertension, increased intracranial pressure, reaction to anesthetics) * previous reaction to medications routinely used in conscious sedation * patients with history of intolerance to either general anesthesia or conscious sedation * dementia or other severe cognitive impairment causing inability to understand or consent to the procedure and study

Keywords: ebus mediastinal lymph nodes mediastinal masses anesthesia moderate sedation
trial of aerobic exercise in patients undergoing outpatient hemodialysis

Conditions: Kidney Failure, Chronic

Summary: randomized controlled trial comparing effects of ergometer exercise during hemodialysis to effects of pedometer use outside of hemodialysis on exercise capacity, functional status, quality of life and adequacy of hemodialysis.

study design: prospective, randomized, controlled trial of chronic hemodialysis outpatients within the manitoba renal program. potential patients include any individual receiving chronic outpatient hemodialysis in winnipeg (seven oaks, sherbrook, central and st. boniface dialysis units) and the brandon hemodialysis unit. exercise interventions: patients will be block randomized to one of the following 2 interventions: group a: cycling on an ergometer goal 60 minutes 3 times per week on hemodialysis for 24 weeks a cycling ergometer will be placed on the floor in front of the patient's dialysis chair or at the foot of the bed (if there are only beds available in that unit). the patient will be allowed to exercise anytime during the first half of each dialysis treatment. goal frequency will be 3 times per week during their usual scheduled hemodialysis treatments. group b: pedometers this group will each receive a pedometer (stepscount®) at the onset of the study following exercise testing. they will be educated regarding the technical use of the pedometer and will receive the handout entitled "pedometer information sheet: get physically active one step at a time!" they will also receive verbal education regarding use of the pedometer and goal activity levels from the exercise study supervisor.

Eligibility criteria:
inclusion criteria: * all adult (\>18 years old) patients * treated with hemodialysis for \> 3 months * hemoglobin \> 100 g/l over the previous 2 months * kt/v \> 1.2 for last month and no history of shortened dialysis due to hemodialysis access issues or frequent alarming during dialysis due to poor access will be eligible for the study. * study patients must also be likely able to complete 12 consecutive weeks of exercise (i.e. no travel, change of modality, elective surgery planned) and must be able to comprehend instructions in english. exclusion criteria: * acute medical illness in last month * unstable hemodialysis with frequent hypotension over the past month * active cardiovascular disease (stroke or acute coronary syndrome, unstable angina) in last 3 months * lower extremity amputation with no prosthesis (inability to pedal a bike) * spine compression fractures * severe musculoskeletal pain at rest or with minimal activity * inability to sit, stand or walk unassisted (walking devices such as cane will be allowed) * shortness of breath at rest or with activities of daily living (nyha class iv) * labile glycemic control with hypoglycaemic episodes \> 1x/week.

Keywords: hemodialysis exercise physical fitness dialysis adequacy
the investigation of the depression in osteoarthritis

Conditions: Depression

Summary: studies have reported that the patient's psychological state such as anxiety, depression and other emotion affect the therapeutic effect of osteoarthritis, also may be the important reason for the poor knee joint osteoarthritis efficacy. the aim of this study are firstly to investigate the depression status of patients with osteoarthritis. secondly, the study will aim to assess whether osteoarthritis progression will affect depression status, ultimately, provide reference for clinical.


Eligibility criteria:
inclusion criteria: meet the 1986 american college of rheumatology (acr) clinical criteria for knee osteoarthritis and the 2010 chinese medical association clinical criteria for knee osteoarthritis. exclusion criteria: patients with rheumatoid arthritis patients with a history of depression before osteoarthritis pathogenesis patients who can't cooperate with related inspection and assessment patients with mental illness
neuroprotective efficacy of postnatal magnesium sulphate in term infants with birth asphyxia

Conditions: Birth Asphyxia

Summary: birth/perinatal asphyxia in pakistan continues to be a leading cause of neonatal mortality and morbidity. it is estimated that around 80 to 120,000 neonates either suffer from or die from birth/perinatal asphyxia every year. in addition to the large number of deaths a larger number of babies who survive suffer from neuro-developmental disorders adding to the health burden to the society and the nation. to date other than prevention (which requires global efforts to improve maternal education and health care) the therapies available to treat infants who have suffered from birth asphyxia have been either technically too complex or extremely expensive.

birth/perinatal asphyxia in pakistan continues to be a leading cause of neonatal mortality and morbidity. it is estimated that around 80 to 120,000 neonates either suffer from or die from birth/perinatal asphyxia every year. in addition to the large number of deaths a larger number of babies who survive suffer from neuro-developmental disorders adding to the health burden to the society and the nation. to date other than prevention (which requires global efforts to improve maternal education and health care) the therapies available to treat infants who have suffered from birth asphyxia have been either technically too complex or extremely expensive. recent evidence from animal studies and small human studies it has become clear that giving magnesium sulphate to term or nearterm babies with moderate to severe birth/perinatal asphyxia reduces both mortality and morbidity. magnesium sulphate as a drug has been in clinical use for decades; its pharmacokinetics, safety profile and mode of action are well known. it is cheap and readily available in pakistan thus providing an opportunity to confirm or refute the efficacy of magnesium sulphate in birth/perinatal asphyxia. with this in mind the following pragmatic study has been designed using the current practices and available resources:

Eligibility criteria:
inclusion criteria: * term and near term infants (≥35 weeks gestation) with moderate to severe birth asphyxia age at admission \< 24 hours exclusion criteria: * babies who could not be given first injection before 24 hours of age infants with major congenital malformations, sepsis, congenital heart defects, intracranial hemorrhage and surgical problems babies received intubated in emergency babies receiving therapeutic hypothermia infants with disorders of metabolism infants in whom cause other than asphyxia is established as the reason for not initiating or sustaining breathing at birth.

Keywords: birth asphyxia magnesium sulphate term infants
huaier granules for prevention of recurrence and metastasis of colorectal cancer patients following radical surgery

Conditions: Colorectal Cancer

Summary: to evaluate the efficacy and safety of huaier granules for prevention of recurrence and metastasis of colorectal cancer patients following radical surgery

this is a multisite, open-label, prospective study investigating huaier granule for prevention of recurrence and metastasis of colorectal cancer patients following radical surgery，to evaluate the efficacy and safety.

Eligibility criteria:
inclusion criteria: 1. males or females ages 18-75 years; 2. the first time to the therapy of patients who received the radical surgery within two months, postoperative histopathology confirms the diagnosis of colorectal cancer with stage iib, iic and iii ( tnm classification) 3. ecog score of 0-2; 4. no history of malignant tumors; 5. the patients are volunteered for the study, sign informed consent form and cooperate with investigator to collect data. exclusion criteria: 1. patients have basic diseases including heart diseases, cerebrovascular disease, lung disease, severe hypertension or diabetes with poor glycemic control; 2. confirmed infections after surgery ; 3. patients who have post-surgery complications or who are currently under the influence of the radical surgery for colorectal cancer; 4. being infected with syphilis or with other blood-borne infectious diseases; 5. pregnancy or lactation; or women of childbearing potential not using contraception; 6. patients who have taken traditional chinese medicines with efficacy and indications similar to that of huaier granule - including, but not limited to, compound banmao capsule., huachansu capsule, kangai injection and pingxiao tablets; 7. patients who are suffering from mental illness or conditions that are considered not suitable for this study investigators.

Keywords: huaier granule multisite open-label prospective
assay of pro-angiogenic cytokines in exudative age-related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: anti-vegf intravitreal injections are the treatment of choice in age-related macular degeneration (amd). however 37% of patients are unresponsive or poorly responsive to these therapies. it is still not possible to foresee the patient's response to anti-vegf injections. a poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. the primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in amd patients.


Eligibility criteria:
inclusion criteria: * age \> 18 years * diagnosis of exudative age-related macular degeneration requiring intravitreal anti-vegf treatment. * patient for whom the last intravitreal injection of anti-vegf in the eye is strictly more than 3 months * signature of informed consent * affiliation to the french social security system exclusion criteria: * pregnant or nursing patient (a urinary pregnancy test will be performed) * systemic treatment with anti-vegf * intravitreal treatment with anti-vegf for less than 3 months regardless of the treated eye. * retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis. * diabetes mellitus * high myopia * simultaneous participation in another clinical research protocol in exudative amd * person under guardianship, under curatorship, deprived of liberty
evaluation of the circulatory status of stomach tube and gastrooesophageal anastomosis

Conditions: Circulatory; Change; Microcirculation

Summary: the incidence of anastomotic leaks after gastroesophageal anastomosis after thoracolaparoscopic cancer esophagus surgery is high at the oslo university hospital. the patients selected for operation shall be investigated for microcirculatory changes at the thoracic anastomosis site and followed up for any post operative anastomotic leaks.

- microcirculation shall be evaluated during the operation with trans serosal laser doppler flowmetry and visible light spectroscopy (ldfvls). different anatomical areas of the stomach and gastric tube shall be examined with ldfvls to find any changes in so2, rhb, flow, and velocity. repeat measurements shall be taken to compare them with the baseline measurements.

Eligibility criteria:
inclusion criteria: patients with oesophageal carcinoma planned to have thoracolaparoscopic operation and thoracic gastroesophageal anastomosis shall be included. exclusion criteria: patients who do not give written consent will not be included.

Keywords: cancer oesophagus
study of paclitaxel, carboplatin, and gemcitabine versus gemcitabine and vinorelbine for non-small cell lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to compare the effectiveness of the three-drug combination paclitaxel, carboplatin, and gemcitabine to the two-drug combination gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer

upon determination of eligibility, patients will be randomly assigned to one of two treatment arms: * paclitaxel + carboplatin + gemcitabine * gemcitabine + vinorelbine for ever 2 patients treated, 1 will receive treatment a (paclitaxel + carboplatin + gemcitabine) and 1 will receive treatment b (gemcitabine + vinorelbine). the study is not blinded so both the patient and the doctor will know which treatment has been assigned.

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * non-small cell bronchogenic carcinoma * newly diagnosed unresectable stage iiib or stage iv disease * patients with stage iiib disease should be ineligible for combined therapy * patients must have measurable lesion definable by x-ray or ct scan. * no prior antineoplastic chemotherapy for lung cancer prior to study entry * age \> 18 years * able to perform activities of daily living with minimal assistance * adequate bone marrow, liver and kidney function * written informed consent must be obtained prior to study entry * patients must be available for treatment and followup. exclusion criteria: you cannot participate in this study if any of the following apply to you: * female patient pregnant or lactating * history of heart disease * serious active infection at the time of treatment * other serious underlying medical condition * brain metastasis * patients without measurable disease * uncontrolled diabetes mellitus defined as random blood sugar \> 250mg/dl * dementia or significantly altered mental status * significant peripheral neuropathy by history or physical examination. please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
a study of abemaciclib (ly2835219) in combination with other anti-cancer therapies in japanese participants with advanced cancer

Conditions: Advanced Cancer

Summary: the purpose of this study is to see if the study drug abemaciclib in combination with other anti-cancer therapies is safe in japanese participants with advanced cancer.


Eligibility criteria:
inclusion criteria: * participant with histologically confirmed adenocarcinoma of the prostate. * participant with metastatic disease documented by positive bone scan and/or measurable soft tissue metastatic lesions by computed tomography (ct) or magnetic resonance imagining (mri). * participant who has serum testosterone level is ≤1.73 nanomoles per liter (nmol/l) (50 nanograms per deciliter). * participant who has progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (adt)/post orchiectomy. * participant with adequate organ function. * participant with eastern cooperative oncology group (ecog) performance status of 0-1. exclusion criteria: * participant who was treated with cytochrome p450 (cyp)17 inhibitors (including abiraterone acetate, tak-700, tok-001, and ketoconazole). * participant who was treated with abemaciclib or any cyclin dependent kinase 4 and 6 (cdk4 and 6) inhibitors. * participant who has prior cytotoxic chemotherapy for metastatic castration-resistant prostate cancer (mcrpc), prior radiopharmaceuticals for prostate cancer (pca), or prior sipuleucel-t. * participant who has gastrointestinal disorder affecting absorption or inability to swallow large pills. * participant who has clinically active or chronic liver disease, moderate/severe hepatic impairment, ascites, or bleeding disorders secondary to hepatic dysfunction. * participant who has known or suspected central nervous system metastatic disease. * participant who was treated with drugs known to be strong inhibitors, or strong or moderate inducers of cytochrome p450 3a4 (cyp3a4) and the treatment cannot be discontinued or switched prior to starting study treatment.